CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023.
| SEATTLE, Feb. 2, 2023 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023: Guggenheim Partners 5th Annual Oncology Conference SVB Securities Global Biopharma Conference The presentations will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com. About CTI BioPharma Corp. We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 109/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. VONJO™ is a trademark of CTI BioPharma Corp. Investor Relations and Media Contacts: Remy Bernarda
SOURCE CTI BioPharma Corp. | ||
Company Codes: NASDAQ-SMALL:CTIC |
View original content to download multimedia:
